Elanco(ELAN) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Elanco reported $1.14 billion in revenue for Q4 2025, a 12% increase on a reported basis, with 9% organic constant currency growth driven primarily by volume increases [23][24] - Full-year revenue reached $4.715 billion, representing 6% growth, with Adjusted EBITDA of $901 million and Adjusted EPS of $0.94, compared to $0.91 in 2024 [26][27] - The net leverage ratio improved to 3.6 times at year-end, with expectations to reduce it to 3.1-3.3 times in 2026 [5][27] Business Line Data and Key Metrics Changes - U.S. Pet Health revenue grew 10% in Q4, driven by key innovation products like Credelio Quattro and Zenrelia, while international pet health grew 8% [23][24][9] - U.S. Farm Animal business achieved 17% growth in Q4, supported by strong performance from Experior and Pradalex, while international farm animal grew 4% [24][9] - Innovation revenue for 2025 was $892 million, with expectations to reach $1.15 billion in 2026 [4][10] Market Data and Key Metrics Changes - The U.S. broad-spectrum parasiticide market grew 30% year-over-year, with Credelio Quattro gaining significant market share [12][11] - Zenrelia achieved over 30% market share in Japan and 40% in Brazil, indicating strong international performance [14][43] - The farm animal market is expected to benefit from increasing animal protein consumption, projected to grow at 5% annually in the U.S. [36] Company Strategy and Development Direction - Elanco is focused on growth, innovation, and cash management, with a commitment to introducing new products and expanding market share [5][20] - The acquisition of AHV International aims to enhance Elanco's portfolio in the dairy industry, particularly in North America and Europe [20] - The company is implementing a productivity initiative, Elanco Ascend, to drive efficiencies and margin enhancement starting in 2026 [20][33] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in Elanco's trajectory, highlighting the company's ability to lead in the animal health industry amid a projected $20 billion market growth over the next decade [34][35] - The company anticipates sustainable revenue growth driven by innovation and strategic pricing, while acknowledging competitive pressures and inflationary challenges [32][75] - Management expects to gain incremental market share in pet health and strengthen leadership in farm animal products [32][36] Other Important Information - Adjusted gross margin for Q4 increased to 51.2%, with operating expenses growing by 10% to support strategic investments [24][25] - The effective tax rate for 2025 was 21.8%, reflecting a year-over-year increase due to non-recurring tax credits recognized in 2024 [27] Q&A Session Summary Question: Insights on Zenrelia's International Share Gains - Management highlighted Zenrelia's efficacy as a key driver for its rapid share gains in international markets, with expectations for continued growth in the U.S. following potential label updates [41][43] Question: Impact of Covetrus and MWI Merger - Management emphasized strong relationships with distributors and the value added through collaboration, indicating confidence in maintaining competitive advantages despite market changes [48][49] Question: Pricing Strategy for 2026 - Management confirmed expectations for accelerating price growth in 2026, driven by the value of new innovations and a comprehensive portfolio [54][55] Question: Stocking Dynamics and Competitive Positioning - Management reported strong demand and multiple orders from distributors, indicating no significant stocking issues as the spring season approaches [64][66] Question: Timeline for Zenrelia Label Update - Management confirmed ongoing constructive dialogue with the FDA regarding the label update, with expectations for alignment with international standards [67][70] Question: Corporate Accounts and Portfolio Gaps - Management noted significant progress in corporate account penetration and highlighted the importance of upcoming products like Befrena in enhancing their competitive position [76][78]